Targeted cancer drugs are supposed to be the win-win for pharma and payers--for pharma, because they're aimed at smaller groups of patients, justifying higher prices and potentially speeding development; for payers, because they only have to foot the bill for patients who are likely to get results. But time-challenged cancer doctors don't want to delay treatment by using a PD-L1 assay to decide which drug to use.
